Beautifi Launches Loan Insurance to Provide Extra Security for Patients and Clinics
VANCOUVER, BC, Sept. 29, 2025 /CNW/ - Beautifi, Canada's leading medical financing provider, is proud to announce the launch of...
Disability
Optifino and Covr Announce Deal to Transform Life Insurance Distribution
Insurtech acquisition unites next-gen AI-powered case design with proven compliance and operational infrastructure NEW YORK, Sept. 29, 2025 /PRNewswire/ --...
MDisrupt Welcomes American Heart Association Professional Members to Its Platform, Unlocking Faster Innovation in Heart and Brain Health
The addition of cardiology and neurology experts helps health companies scale evidence-based health products with confidence AUSTIN, Texas, Sept. 25,...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active...
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,...
Levicept to Present Key New Data from Phase II Trial of LEVI-04, a Novel Neurotrophin-3 Inhibitor, at ACR Convergence 2025
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients...
Renaissance Expands RenConnect℠ to Deliver More Efficient Benefits Administration
Small-group EDI integration breaks market norms bringing automation and accuracy to ancillary benefits administration for groups of any size. INDIANAPOLIS, Sept....
Planning With Purpose: NAELA and SNA Partner to Promote Special Needs Law Month
VIENNA, Va., Sept. 24, 2025 /PRNewswire/ -- The National Academy of Elder Law Attorneys (NAELA) and the Special Needs Alliance...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved...
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
APhA alarmed by claims of harm from acetaminophen without substantive science
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- As the medication experts, APhA affirms there has been no new evidence in two...
ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system...
National Multiple Sclerosis Society Leads the Way in Making it Easier to Diagnose MS
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and...
TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched...
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA...
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...